OTCMKTS:INNV

InnovAge Competitors

$24.27
-0.52 (-2.10 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.14
Now: $24.27
$24.96
50-Day Range
$1.23
MA: $22.75
$26.04
52-Week Range
$20.86
Now: $24.27
$27.18
Volume41,980 shs
Average Volume303,115 shs
Market Capitalization$3.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1

Competitors

InnovAge (OTCMKTS:INNV) Vs. OPHLF, GRFS, TEVA, RDY, BHC, and MRVI

Should you be buying INNV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to InnovAge, including Ono Pharmaceutical (OPHLF), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), and Maravai LifeSciences (MRVI).

InnovAge (OTCMKTS:INNV) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for InnovAge and Ono Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InnovAge01502.83
Ono Pharmaceutical0000N/A

InnovAge currently has a consensus price target of $29.80, suggesting a potential upside of 22.79%. Given InnovAge's higher probable upside, equities research analysts plainly believe InnovAge is more favorable than Ono Pharmaceutical.

Profitability

This table compares InnovAge and Ono Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InnovAge-35.85%-1,611.96%-77.85%
Ono Pharmaceutical22.14%11.29%9.71%

Volatility & Risk

InnovAge has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Earnings and Valuation

This table compares InnovAge and Ono Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83
Ono Pharmaceutical$2.69 billion4.79$549.28 million$1.0922.98

Ono Pharmaceutical has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Ono Pharmaceutical beats InnovAge on 7 of the 11 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and InnovAge (OTCMKTS:INNV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Earnings and Valuation

This table compares Grifols and InnovAge's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$5.71 billion2.18$700.16 million$1.1715.45
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83

Grifols has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Grifols and InnovAge, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Grifols03502.63
InnovAge01502.83

InnovAge has a consensus target price of $29.80, indicating a potential upside of 22.79%. Given InnovAge's stronger consensus rating and higher probable upside, analysts plainly believe InnovAge is more favorable than Grifols.

Profitability

This table compares Grifols and InnovAge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Grifols12.79%10.65%4.79%
InnovAge-35.85%-1,611.96%-77.85%

Risk & Volatility

Grifols has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, InnovAge has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Institutional and Insider Ownership

15.2% of Grifols shares are owned by institutional investors. 12.8% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Grifols beats InnovAge on 8 of the 13 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and InnovAge (OTCMKTS:INNV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 12.8% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and InnovAge's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.66$-998,000,000.00$2.314.39
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83

InnovAge has lower revenue, but higher earnings than Teva Pharmaceutical Industries. InnovAge is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Teva Pharmaceutical Industries and InnovAge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
InnovAge-35.85%-1,611.96%-77.85%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Teva Pharmaceutical Industries and InnovAge, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries18402.23
InnovAge01502.83

Teva Pharmaceutical Industries presently has a consensus target price of $12.2222, suggesting a potential upside of 21.98%. InnovAge has a consensus target price of $29.80, suggesting a potential upside of 22.79%. Given InnovAge's stronger consensus rating and higher probable upside, analysts plainly believe InnovAge is more favorable than Teva Pharmaceutical Industries.

Dr. Reddy's Laboratories (NYSE:RDY) and InnovAge (OTCMKTS:INNV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Volatility & Risk

Dr. Reddy's Laboratories has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, InnovAge has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and InnovAge's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.87$259 million$2.7924.29
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83

Dr. Reddy's Laboratories has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Dr. Reddy's Laboratories and InnovAge, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
InnovAge01502.83

Dr. Reddy's Laboratories currently has a consensus price target of $70.00, indicating a potential upside of 3.70%. InnovAge has a consensus price target of $29.80, indicating a potential upside of 22.79%. Given InnovAge's higher possible upside, analysts plainly believe InnovAge is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and InnovAge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
InnovAge-35.85%-1,611.96%-77.85%

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 12.8% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats InnovAge on 9 of the 14 factors compared between the two stocks.

InnovAge (OTCMKTS:INNV) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. 12.8% of InnovAge shares are held by insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for InnovAge and Bausch Health Companies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InnovAge01502.83
Bausch Health Companies14702.50

InnovAge presently has a consensus price target of $29.80, suggesting a potential upside of 22.79%. Bausch Health Companies has a consensus price target of $32.5833, suggesting a potential upside of 16.16%. Given InnovAge's stronger consensus rating and higher possible upside, research analysts plainly believe InnovAge is more favorable than Bausch Health Companies.

Profitability

This table compares InnovAge and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InnovAge-35.85%-1,611.96%-77.85%
Bausch Health Companies-23.92%173.20%4.21%

Risk and Volatility

InnovAge has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Earnings & Valuation

This table compares InnovAge and Bausch Health Companies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83
Bausch Health Companies$8.60 billion1.17$-1,788,000,000.00$4.436.38

InnovAge has higher earnings, but lower revenue than Bausch Health Companies. InnovAge is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Bausch Health Companies beats InnovAge on 8 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and InnovAge (OTCMKTS:INNV) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Maravai LifeSciences and InnovAge, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
InnovAge01502.83

Maravai LifeSciences presently has a consensus target price of $38.1250, indicating a potential upside of 8.03%. InnovAge has a consensus target price of $29.80, indicating a potential upside of 22.79%. Given InnovAge's higher probable upside, analysts plainly believe InnovAge is more favorable than Maravai LifeSciences.

Valuation and Earnings

This table compares Maravai LifeSciences and InnovAge's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
InnovAge$23.99 million134.74$-8,280,000.00($4.16)-5.83

Maravai LifeSciences has higher earnings, but lower revenue than InnovAge.

Profitability

This table compares Maravai LifeSciences and InnovAge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
InnovAge-35.85%-1,611.96%-77.85%

Summary

Maravai LifeSciences beats InnovAge on 5 of the 7 factors compared between the two stocks.


InnovAge Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OPHLF
Ono Pharmaceutical
1.1$25.05-0.0%$12.88 billion$2.69 billion22.77
Grifols logo
GRFS
Grifols
1.3$18.08-1.8%$12.65 billion$5.71 billion16.14Analyst Report
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.15-1.3%$11.23 billion$16.89 billion-2.76Decrease in Short Interest
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$67.76-2.6%$10.97 billion$2.32 billion56.00Gap Down
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.28-3.0%$10.36 billion$8.60 billion-5.19
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.42-3.6%$9.45 billionN/A0.00Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$166.00-0.7%$9.42 billion$2.16 billion52.37Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.40-1.7%$9.08 billion$1.45 billion19.62
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.30-2.2%$8.27 billion$40.56 million-15.92Gap Up
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$154.82-0.1%$7.85 billion$3.34 million-20.11News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.95-1.4%$7.06 billion$103.71 million-23.68Analyst Report
Insider Selling
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.82-0.3%$6.95 billion$87.99 million-79.55
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.45-0.0%$6.85 billion$311.33 million-127.01
Evotec logo
EVTCY
Evotec
0.5$80.15-0.0%$6.59 billion$500.07 million445.30News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$123.16-1.3%$6.54 billion$14.98 million-15.00News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.79-5.0%$6.02 billion$150,000.00-19.24Analyst Report
News Coverage
Allakos logo
ALLK
Allakos
1.7$104.32-0.8%$5.63 billionN/A-38.07Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.84-2.2%$5.63 billion$1.12 billion85.08Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.26-0.1%$5.58 billion$380.83 million-8.98Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.91-0.5%$5.57 billion$4.84 billion-698.38Dividend Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.15-1.8%$5.44 billion$66.51 million17.00Analyst Report
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.19-0.5%$5.16 billion$1.00 billion-12.00Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$70.44-3.0%$5.08 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$73.11-1.1%$4.49 billionN/A-5.96Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.41-2.2%$4.38 billion$6.87 million-7.09Analyst Report
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$28.98-0.4%$4.24 billion$204.89 million-36.23Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.10-1.7%$4.18 billion$4.31 million-1.98Increase in Short Interest
Hypera logo
HYPMY
Hypera
0.9$6.31-0.6%$3.97 billion$834.89 million14.67Upcoming Earnings
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.76-0.6%$3.94 billion$806.43 million-9.31Analyst Report
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.06-1.0%$3.81 billion$117.91 million-11.17
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.60-0.8%$3.70 billionN/A-6.15
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$42.16-5.6%$3.68 billionN/A0.00Increase in Short Interest
Gap Down
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.47-3.7%$3.64 billion$1.11 billion21.05News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$71.48-1.7%$3.56 billionN/A-20.36
LEGN
Legend Biotech
1.2$26.36-1.3%$3.46 billion$64.39 million0.00Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.93-0.7%$3.43 billion$114.62 million-7.63
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.90-1.4%$3.34 billion$306.98 million-6.71
Insmed logo
INSM
Insmed
1.2$32.17-0.2%$3.33 billion$136.47 million-12.37News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.72-0.0%$3.32 billion$339.08 million-12.05
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.71-1.7%$3.30 billion$26.52 million-7.90Unusual Options Activity
Alkermes logo
ALKS
Alkermes
1.2$20.32-1.3%$3.19 billion$1.17 billion-44.17Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.27-1.0%$3.12 billion$36.13 million-67.57
Arvinas logo
ARVN
Arvinas
1.5$61.61-0.9%$3.04 billion$42.98 million-24.07Upcoming Earnings
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.58-0.1%$2.97 billion$80.43 million107.53
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.02-1.6%$2.94 billionN/A-53.24
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.04-0.2%$2.90 billion$644.77 million-10.85
OPKO Health logo
OPK
OPKO Health
1.9$4.14-1.4%$2.81 billion$901.90 million-23.00
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.63-1.4%$2.79 billion$421.03 million22.05
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.59-1.4%$2.69 billion$306.49 million25.38
Organogenesis logo
ORGO
Organogenesis
1.0$20.05-4.6%$2.69 billion$260.98 million-334.17Analyst Downgrade
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.